El interés en corto de UnitedHealth Group da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de UnitedHealth Group. Los datos de interés en corto se actualizan cada dos semanas.

UnitedHealth Group (NYSE:UNH) Bolsa, Informe de interés en corto

UnitedHealth Group

UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group Inc

EC Healthcare

United Hampshire US REIT

UNITEDHEALTH GRP ORD

On Tuesday, the U.S. Justice Department said it will block UnitedHealth Group Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) multi-billion&nbsp;acquisition of&nbsp;Amedisys Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>).
The Justice Department has sued to block UnitedHealth&#8217;s $3.3 billion purchase of healthcare services company Amedisys, citing concerns about competition in the home <a target="_blank" href="https://www.benzinga.com/news/legal/24/11/41917050/justice-department-moves-to-block-unitedhealths-amedisys-takeover-whats-going-on" rel="noreferrer noopener">health services market</a>.
UnitedHealth&#8217;s Optum unit&nbsp;launched a website&nbsp;that aims to highlight the benefits of the combination. The website <a target="_blank" href="https://www.improvinghomecare.com/" rel="noreferrer noopener">notes</a> that the home healthcare industry remains highly fragmented despite the growing market.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
On average, 26 agencies compete in metropolitan areas with about 500,000 residents, highlighting the range of available care options.
In 2020, approximately 3 million Americans received home health care, a figure expected to grow as the population ages.
By 2030, 18% of the U.S. population will be 65 or older, a significant increase from 13% in 2021.
This demographic shift underscores the necessity for expanded home health services that allow older adults to remain in their homes.
The merger between Optum and Amedisys represents a strategic move to address these needs.
While this combined entity would represent only a portion of the overall home health and hospice care market, the competitive landscape is expected to remain robust.
To promote competition and prevent market dominance, Optum and Amedisys have agreed to divest numerous home health and hospice centers to VitalCaring upon the transaction&#8217;s completion.
VitalCaring currently operates at around 58 locations across six states.
Price Action: UNH stock is down 2.76% at $589.17 at the last check Thursday
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41979149/general-motors-faces-recall-crisis-with-faulty-transmissions-details" target="_blank" rel="noreferrer noopener">General Motors Faces Recall Crisis With Faulty Transmissions: Details</a></li>
</ul>
Image via Shutterstock

Large Cap

News

Health Care

Legal

General

AMED

UnitedHealth's Optum Defends Multi-Billion Dollar Amedisys Deal, Ensures Competitive Landscape

Trading Ideas

AMZN

AVGO

CPAY

TTWO

Tiger Global 13F Shows Increased Stake In UnitedHealth Group From 2,347,600 To 2,365,400 Shares; Amazon From 6,321,080 To 6,415,488 Shares; Take-Two Interactive Software From 5,643,542 To 5,839,256 Shares; Eli Lilly & Co From 930,000 To 969,800 Shares; Taiwan Semiconductor Manufacturing From 3,070,890 To 3,634,980 Shares; Corpay From 1,046,600 To 1,247,577 Shares; Broadcom From 182,300 To 1,845,500 Shares

UnitedHealth Says 'Will Vigorously Defend Against The DOJ's Overreaching'

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) shares are trading lower Tuesday. The U.S. Justice Department is moving to block the company&#8217;s multi-billion <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/06/32716991/optums-decision-to-target-amedisys-is-intriguing-says-analyst">acquisition of Amedisys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>)</a>.
What To Know: The Justice Department has sued to block UnitedHealth&#8217;s $3.3 billion purchase of healthcare services company Amedisys, citing concerns related to competition in the home health services market, according to <a href="https://www.wsj.com/business/justice-department-sues-to-block-unitedhealths-3-3-billion-bid-for-amedisys-b0b1f738">The Wall Street Journal</a>.
Antitrust enforcers are concerned that a potential business combination could cause healthcare price increases in the areas where Amedisys competes with UnitedHealth's LHC Group.
&#8220;Unless this $3.3 billion transaction is stopped, UnitedHealth Group will further extend its grip to home health and hospice care, threatening seniors, their families and nurses," Assistant Attorney General&nbsp;Jonathan Kanter&nbsp;said.
The Justice Department reportedly filed the complaint in Maryland federal court, supported by state attorneys general of Maryland, Illinois, New Jersey and New York. 
The report indicates that UnitedHealth and Amedisys executives met with the Justice Department last week, aiming to ease concerns. The companies proposed selling some of their other assets to VitalCaring Group.
See Also: <a href="https://www.benzinga.com/news/global/24/11/41912971/stocks-fall-on-tariffs-fears-dollar-hits-6-month-peak-yen-tumbles-whats-driving-markets-tuesday">Stocks Fall On Tariffs Fears, Dollar Hits 6-Month Peak, Yen Tumbles: What&#8217;s Driving Markets Tuesday?</a>
UnitedHealth entered into an agreement to acquire Amedisys last year. At the time, analysts raised concerns that the deal was likely to face scrutiny given the company&#8217;s robust home healthcare presence.
United Health bought LHC Group for about $5.4 billion in 2022. Amedisys is a main competitor&nbsp;to UnitedHealth&#8217;s LHC Group. Amedisys shares were down 2.21% at $90.54 at last check.
UNH Price Action: UnitedHealth shares were down 1.18% at $617.85 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of UnitedHealth.

Movers

Justice Department Moves To Block UnitedHealth's Amedisys Takeover: What's Going On?

<a href="https://www.wsj.com/business/justice-department-sues-to-block-unitedhealths-3-3-billion-bid-for-amedisys-b0b1f738?mod=latest_headlines">https://www.wsj.com/business/justice-department-sues-to-block-unitedhealths-3-3-billion-bid-for-amedisys-b0b1f738?mod=latest_headlines</a>
&nbsp;
The Justice Department on Tuesday sued to block <a href="https://www.wsj.com/market-data/quotes/UNH">UnitedHealth Group</a>'s $3.3 billion acquisition of <a href="https://www.wsj.com/market-data/quotes/AMED">Amedisys</a> alleging the deal would give the <a href="https://www.wsj.com/health/healthcare/unitedhealth-shares-dive-after-health-giant-says-2025-results-likely-to-fall-short-8a7ff76a?mod=article_inline">health-industry giant</a> too much power over the market for home health and hospice services.
The government's move represents an effort to stem the roll-up of different healthcare services under a single owner. UnitedHealth last year acquired one of Amedisys's major competitors, LHC Group.&nbsp;

"Justice Department Sues To Block UnitedHealth's $3.3B Bid For Amedisys; Antitrust Enforcers Argue The Healthcare Giant's Latest Deal Would Illegally Harm Competition" - WSJ

Financial giants have made a conspicuous bullish move on UnitedHealth Group. Our analysis of options history for UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) revealed 28 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 32% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $160,867, and 24 were calls, valued at $6,833,141.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $240.0 to $720.0 for UnitedHealth Group over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in UnitedHealth Group's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to UnitedHealth Group's substantial trades, within a strike price spectrum from $240.0 to $720.0 over the preceding 30 days.
<h3>UnitedHealth Group 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731434474_0_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$382.0</td>
<td>$378.1</td>
<td>$382.0</td>
<td>$240.00</td>
<td>$1.1M</td>
<td>6.0K</td>
<td align="right">30</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$382.0</td>
<td>$377.1</td>
<td>$382.0</td>
<td>$240.00</td>
<td>$955.0K</td>
<td>6.0K</td>
<td align="right">300</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$382.0</td>
<td>$377.1</td>
<td>$382.0</td>
<td>$240.00</td>
<td>$955.0K</td>
<td>6.0K</td>
<td align="right">275</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$382.0</td>
<td>$377.1</td>
<td>$382.0</td>
<td>$240.00</td>
<td>$955.0K</td>
<td>6.0K</td>
<td align="right">250</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$382.0</td>
<td>$377.1</td>
<td>$382.0</td>
<td>$240.00</td>
<td>$955.0K</td>
<td>6.0K</td>
<td align="right">225</td>
</tr>
</tbody>
</table>

<h3>About UnitedHealth Group</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
In light of the recent options history for UnitedHealth Group, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>UnitedHealth Group's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,193,221, with UNH's price down by -1.11%, positioned at $618.3.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 59 days.</li>
</ul>
<h3>What The Experts Say On UnitedHealth Group</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $616.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Truist Securities lowers its rating to Buy with a new price target of $625. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on UnitedHealth Group, which currently sits at a price target of $610. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on UnitedHealth Group, which currently sits at a price target of $650. 
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for UnitedHealth Group, targeting a price of $595. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on UnitedHealth Group with a target price of $603. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest UnitedHealth Group options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Behind the Scenes of UnitedHealth Group's Latest Options Trends

Financial giants have made a conspicuous bullish move on UnitedHealth Group. Our analysis of options history for UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) revealed 13 unusual trades.
Delving into the details, we found 46% of traders were bullish, while 15% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $146,790, and 9 were calls, valued at $431,920.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $300.0 to $640.0 for UnitedHealth Group during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for UnitedHealth Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across UnitedHealth Group's significant trades, within a strike price range of $300.0 to $640.0, over the past month.
<h3>UnitedHealth Group Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731337236_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$121.7</td>
<td>$116.45</td>
<td>$120.0</td>
<td>$550.00</td>
<td>$84.0K</td>
<td>173</td>
<td>7</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.35</td>
<td>$5.85</td>
<td>$6.35</td>
<td>$630.00</td>
<td>$63.0K</td>
<td>4.4K</td>
<td>2.9K</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$37.35</td>
<td>$34.95</td>
<td>$36.24</td>
<td>$600.00</td>
<td>$54.3K</td>
<td>1.3K</td>
<td>39</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$37.4</td>
<td>$34.9</td>
<td>$36.23</td>
<td>$600.00</td>
<td>$54.3K</td>
<td>1.3K</td>
<td>24</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$122.3</td>
<td>$119.2</td>
<td>$122.3</td>
<td>$500.00</td>
<td>$48.9K</td>
<td>2.0K</td>
<td>4</td>
</tr>
</tbody>
</table>

<h3>About UnitedHealth Group</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
In light of the recent options history for UnitedHealth Group, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of UnitedHealth Group</h3>
<ul>
<li>With a volume of 206,951, the price of UNH is up 1.22% at $623.31. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 60 days.</li>
</ul>
<h3>Expert Opinions on UnitedHealth Group</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $627.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Truist Securities downgraded its rating to Buy, setting a price target of $625. 
&#x2A; Maintaining their stance, an analyst from TD Cowen continues to hold a Buy rating for UnitedHealth Group, targeting a price of $609. 
&#x2A; An analyst from Keybanc has decided to maintain their Overweight rating on UnitedHealth Group, which currently sits at a price target of $650. 
&#x2A; An analyst from Stephens &amp; Co. has decided to maintain their Overweight rating on UnitedHealth Group, which currently sits at a price target of $605. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on UnitedHealth Group, which currently sits at a price target of $650. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for UnitedHealth Group with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Unpacking the Latest Options Trading Trends in UnitedHealth Group

On Wednesday, Donald Trump, the Republican candidate and former president, was elected to the highest office again, marking a return to an administration. His second term is likely to impact U.S. healthcare.
Trump has been unclear about his healthcare policy goals during his campaign. Healthcare <a target="_blank" href="https://www.kff.org/health-care-in-2024-elections-apvotecast-polling/?entry=kff-analysis-of-ap-votecast-abortion-ballot-initiatives" rel="noreferrer noopener">ranked</a> lower than issues like the economy and immigration in voter concerns.
A <a target="_blank" href="https://apnews.com/article/ap-votecast-elections-harris-trump-voters-d5cf4e3611f50ec4349d93ddc7f037cd" rel="noreferrer noopener">poll</a> from the Associated Press found that only 8% of voters viewed healthcare as their top issue, compared to 39% who chose the economy and 20% who picked immigration. Abortion was the leading issue for 11% of voters.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction" rel="noreferrer noopener">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a>
Despite his focus on &#8220;Make America Healthy Again,&#8221; millions of Americans may lose health insurance subsidies next year, depending on the political climate after the election and the Republicans&#8217; control of the Senate.
The subsidies, expanded under the 2021 American Rescue Plan, help many, particularly the middle class, afford health insurance through the Affordable Care Act (ACA).
These subsidies are set to expire at the end of 2025, and it remains uncertain whether they will be extended under the new administration.
Trump and other Republicans have opposed continuing the subsidies.
The NBC News <a target="_blank" href="https://www.nbcnews.com/health/health-news/millions-risk-losing-health-insurance-trumps-victory-rcna179146" rel="noreferrer noopener">report</a>, citing some analysts, suggests that the chances of extension could be less than 5% if Republicans win control of the House and the Senate.
Even if Democrats control the House, extending these subsidies seems unlikely. Without an extension, nearly 4 million Americans could lose coverage by 2026 due to unaffordable premiums.
The 2021 changes led to a surge in ACA enrollment, with 15.5 million people benefiting from subsidies across 32 states. The report adds that if the subsidies aren&#8217;t renewed, up to 15.4 million Americans could lose health coverage by 2030.
Another significant issue is Trump&#8217;s stance on Medicare. As president, he supported Medicare Advantage, a private insurer-run program that could eventually replace traditional, government-run Medicare.
The NPR report <a target="_blank" href="https://www.npr.org/sections/shots-health-news/2024/11/07/nx-s1-5183092/trump-election-2024-medicare-advantage" rel="noreferrer noopener">highlights</a> that critics argue that expanding private insurers could increase costs for taxpayers and limit care, with some beneficiaries finding it difficult to switch back to traditional Medicare.
Robert Berenson, a former government official, warned that traditional Medicare could &#8220;wither on the vine.&#8221;
Medicare Advantage grew with the 2003 legislation introducing a drug benefit and expanded private insurers&#8217; role in the program. Although private plans were expected to lower costs, they have been more expensive.
The report also says that in 2023, Medicare Advantage plans cost taxpayers about 6% — or $27 billion — more than traditional Medicare, though some research suggests they offer better care.
The future of healthcare policy in the U.S. will depend on the political dynamics in Congress and Trump&#8217;s second term.
With Republicans pushing for major changes to the ACA and Medicare, experts warn of significant shifts in how Americans access and pay for healthcare in the coming years.
Read Next
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41855578/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap-but-novo-nordisk-and-lilly-suffer-market-setbacks" target="_blank" rel="noreferrer noopener">Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks</a></li>
</ul>
Photo via Shutterstock

Government

Regulations

Politics

ALHC

CLOV

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Laboratory Corporation Of America Holdings

Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare

Deep-pocketed investors have adopted a bearish approach towards UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in UNH usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 52 extraordinary options activities for UnitedHealth Group. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 44% leaning bullish and 50% bearish. Among these notable options, 16 are puts, totaling $721,919, and 36 are calls, amounting to $2,134,986.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $480.0 to $650.0 for UnitedHealth Group during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for UnitedHealth Group's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of UnitedHealth Group's whale trades within a strike price range from $480.0 to $650.0 in the last 30 days. 
<h3>UnitedHealth Group Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730839752_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$17.05</td>
<td>$17.0</td>
<td>$17.0</td>
<td>$567.50</td>
<td>$278.8K</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">173</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$17.15</td>
<td>$17.1</td>
<td>$17.1</td>
<td>$565.00</td>
<td>$237.6K</td>
<td style="text-align: right;">187</td>
<td style="text-align: right;">158</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$14.95</td>
<td>$14.5</td>
<td>$14.5</td>
<td>$565.00</td>
<td>$145.0K</td>
<td style="text-align: right;">148</td>
<td style="text-align: right;">241</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$11.05</td>
<td>$10.7</td>
<td>$11.05</td>
<td>$562.50</td>
<td>$102.7K</td>
<td style="text-align: right;">50</td>
<td style="text-align: right;">127</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$19.3</td>
<td>$19.2</td>
<td>$19.3</td>
<td>$557.50</td>
<td>$88.5K</td>
<td style="text-align: right;">174</td>
<td style="text-align: right;">97</td>
</tr>
</tbody>
</table>

<h3>About UnitedHealth Group</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
<h3>Where Is UnitedHealth Group Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,471,322, the price of UNH is up by 1.84%, reaching $568.04.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 66 days from now.</li>
</ul>
<h3>What Analysts Are Saying About UnitedHealth Group</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $637.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald persists with their Overweight rating on UnitedHealth Group, maintaining a target price of $644. 
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on UnitedHealth Group with a target price of $650. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for UnitedHealth Group, targeting a price of $650. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for UnitedHealth Group, targeting a price of $650. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on UnitedHealth Group, maintaining a target price of $595. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for UnitedHealth Group, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

A Closer Look at UnitedHealth Group's Options Market Dynamics

<a href="https://www.bloomberg.com/news/articles/2024-11-05/unitedhealth-unilaterally-cut-doctors-pay-for-er-mental-health-records-show" title="https://www.bloomberg.com/news/articles/2024-11-05/unitedhealth-unilaterally-cut-doctors-pay-for-er-mental-health-records-show">https://www.bloomberg.com/news/articles/2024-11-05/unitedhealth-unilaterally-cut-doctors-pay-for-er-mental-health-records-show</a>

'UnitedHealth Emails Reveal Tension Over Cuts To Doctor Pay; Documents Unsealed In Litigation With A Blackstone-Backed Physician Group Show Controversy Inside The Company Over Reducing Payment Rates' - Bloomberg News

Technology giant NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is set to join the Dow Jones Industrial Average on Nov. 8 replacing Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), a move predicted by several market experts to <a href="https://www.benzinga.com/top-stories/24/05/39011237/exclusive-nvidia-dow-jones-inclusion-a-matter-of-when-will-it-replace-intel">Benzinga months ago.</a>
Here's a look at what the Dow Jones Industrial Average inclusion means for Nvidia and why another addition to the index could be more important.
What Happened: Nvidia <a href="https://www.benzinga.com/markets/equities/24/11/41699259/nvidia-rides-ai-wave-to-replace-intel-on-dow-jones-industrial-average-ending-its-25-year-run">will replace Intel</a> in the Dow Jones Industrial Average, a move that may have been predicted by a 10-for-1 stock split by the tech giant earlier this year.
"Price wise, shares are at that elevated level where they have announced a split in the past. Rumor wise, a stock split would make shares more attractive to be added to the Dow Jones Industrial Average," Freedom Capital Markets Chief Strategist Jay Woods said before the split was announced.
Woods told Benzinga Nvidia was a prime candidate to be included in the Dow Jones Industrial Average, which is tracked by the SPDR Dow Jones Industrial Average ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>).
"When you're the face of the next wave of growth in technology, that being AI, that being the chipmaker, that to me says you should be represented in the Dow Jones Industrial Average," Woods previously told Benzinga.
Launched in 1896, the <a href="https://www.benzinga.com/topic/dow-jones-industrial-average">Dow Jones Industrial Average</a> is a well-known stock market index that includes 30 blue-chip U.S. companies. The index often changes to include the best barometers of American growth.
One of the key differences between the Dow Jones Industrial Average and other market indexes like the S&amp;P 500 is the Dow is price-weighted and does not account for changes in market capitalization.
This means that company's that have higher share prices have larger weightings than those with smaller stock prices. So while Nvidia's stock split may have helped the company get into the index, it will now hurt the company's position in the index.
Based on data from <a href="https://www.slickcharts.com/dowjones">Slickcharts</a>, Nvidia would be the 21st largest company by weighting in the index if it were added today. The stock would position after Chevron ($153.33) and ahead of 3M Co ($126.94) with a price of $138.76 at the time of writing. Nvidia would have an estimated weighting of between 1.98% and 2.38% based on the current weighting of 3M and Chevron respectively.
Compare that to UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), currently the largest weighting in the Dow Jones Industrial Average at $556.81 and 8.8%.
Intel, which is being replaced by Nvidia, is currently ranked last in the index with a price of $22.54 and weighting of 0.36%.
As one of the largest companies in the world, Nvidia is the second largest weighting in the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500 Index, representing 6.8% of assets in the ETF. Nvidia is also the second largest weighting in the Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>), which tracks the tech sector, with the stock having a weighting of 14.25%.
Are you buying when the CEOs of the Magnificent 7 are selling?Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a>
Another Dow Index Addition: While investors are excited about Nvidia joining the Dow Jones Industrial Average, they might want to look at Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>), which will have a large weighting in the index and see heavier buying from ETFs that cover the index.
Sherwin-Williams has a current share price of $372.97, which will give the company a higher weighting in the index. The stock would currently rank sixth in the index between Caterpillar ($377.72) and Amgen ($317.75). If Sherwin-Williams were added today, the stock would have an estimated weighting of between 4.97% and 5.91%.
Sherwin-Williams is replacing Dow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) in the index, which currently ranks 28th with a price of $48.10 and a weighting of 0.76%.
The new weightings will depend on prices ahead of the Nov. 8 changes and also be impacted by two of the smaller holdings exiting the index.
Why It's Important: Intel has been a member of the Dow Jones Industrial Average since 1999 but has lagged in stock performance in recent years.
Nvidia is more relevant than Intel and used by the biggest companies, Woods previously told Benzinga.
"The growth is there, the story is there, and now the price is there," Woods said.
Benzinga's "PreMarket Prep" co-host Dennis Dick also predicted Nvidia replacing Intel in the index earlier this year.
"I'd expect this announcement sometime in the summer. I don't think it's a matter of ‘if' NVDA goes into the Dow, I think it's now a matter of ‘when,'" Dick said.
Nvidia shares are up 188.1% year-to-date in 2024 and up 2,573.6% over the past five years. Intel stock is down 52.9% year-to-date in 2024 and down 61.4% over the past five years.
Sherwin-Williams stock is up 22.3% year-to-date in 2024 and up 92.5% over the past five years. Dow stock is down 14.0% year-to-date in 2024 and down 15.0% over the last five years.
The negative performance for Intel and Dow may explain why the Dow Jones Industrial Average has underperformed the S&amp;P 500 index. The Dow Jones Industrial Average ETF is up 11.1% year-to-date and up 51.2% over the past five years. Compare that to the SPY, which is up 20.8% year-to-date and up 84.9% over the past five years.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/11/41718416/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-october-2024-where-do-tesla-nvidia-apple-d">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

ETFs

SPDR Dow Jones Industrial Average ETF Trust

INTC

NVDA

Nvidia Joining Dow Jones Industrial Average: Where Tech Giant Ranks In The Index, Why Sherwin-Williams Addition Could Be More Important

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 20 years by 5.85% on an annualized basis producing an average annual return of 14.17%. Currently, UnitedHealth Group has a market capitalization of $519.85 billion. 
Buying $100 In UNH: If an investor had bought $100 of UNH stock 20 years ago, it would be worth $1,416.61 today based on a price of $562.96 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730320221_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 20 Years

In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) against its key competitors in the Health Care Providers &amp; Services industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>UnitedHealth Group Background</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>UnitedHealth Group Inc</td>
<td>36.55</td>
<td>5.20</td>
<td>1.34</td>
<td>4.79%</td>
<td>$7.67</td>
<td>$21.06</td>
<td>6.61%</td>
</tr>
<tr>
<td>Centene Corp</td>
<td>10.47</td>
<td>1.12</td>
<td>0.20</td>
<td>4.22%</td>
<td>$2.0</td>
<td>$4.43</td>
<td>5.92%</td>
</tr>
<tr>
<td>Molina Healthcare Inc</td>
<td>16.44</td>
<td>3.87</td>
<td>0.48</td>
<td>6.78%</td>
<td>$0.51</td>
<td>$1.19</td>
<td>20.96%</td>
</tr>
<tr>
<td>HealthEquity Inc</td>
<td>72.60</td>
<td>3.53</td>
<td>6.98</td>
<td>1.68%</td>
<td>$0.11</td>
<td>$0.2</td>
<td>23.15%</td>
</tr>
<tr>
<td>Progyny Inc</td>
<td>24.83</td>
<td>3.10</td>
<td>1.38</td>
<td>3.21%</td>
<td>$0.02</td>
<td>$0.07</td>
<td>8.85%</td>
</tr>
<tr>
<td>Average</td>
<td>31.08</td>
<td>2.9</td>
<td>2.26</td>
<td>3.97%</td>
<td>$0.66</td>
<td>$1.47</td>
<td>14.72%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>After examining UnitedHealth Group, the following trends can be inferred: 
<ul>
<li>
Notably, the current Price to Earnings ratio for this stock, 36.55, is 1.18x above the industry norm, reflecting a higher valuation relative to the industry.
</li>
<li>
The elevated Price to Book ratio of 5.2 relative to the industry average by 1.79x suggests company might be overvalued based on its book value.
</li>
<li>
With a relatively low Price to Sales ratio of 1.34, which is 0.59x the industry average, the stock might be considered undervalued based on sales performance.
</li>
<li>
The company has a higher Return on Equity (ROE) of 4.79%, which is 0.82% above the industry average. This suggests efficient use of equity to generate profits and demonstrates profitability and growth potential.
</li>
<li>
Compared to its industry, the company has higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $7.67 Billion, which is 11.62x above the industry average, indicating stronger profitability and robust cash flow generation.
</li>
<li>
With higher gross profit of $21.06 Billion, which indicates 14.33x above the industry average, the company demonstrates stronger profitability and higher earnings from its core operations.
</li>
<li>
The company's revenue growth of 6.61% is significantly below the industry average of 14.72%. This suggests a potential struggle in generating increased sales volume.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730300423_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio is an important measure to assess the financial structure and risk profile of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
By evaluating UnitedHealth Group against its top 4 peers in terms of the Debt-to-Equity ratio, the following observations arise:
<ul>
<li>
Among its top 4 peers, UnitedHealth Group has a higher debt-to-equity ratio of 0.84.
</li>
<li>
This suggests a greater reliance on debt financing, which can expose the company to increased financial risk and potential volatility.
</li>
</ul>
<h3>Key Takeaways</h3>
For UnitedHealth Group, the PE, PB, and PS ratios indicate high valuation compared to peers in the Health Care Providers &amp; Services industry. This suggests potential overvaluation based on these metrics. On the other hand, the high ROE, EBITDA, and gross profit, along with low revenue growth, highlight strong profitability and operational efficiency relative to industry competitors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Analysis: UnitedHealth Group Versus Competitors In Health Care Providers &amp; Services Industry

Deep-pocketed investors have adopted a bullish approach towards UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in UNH usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 24 extraordinary options activities for UnitedHealth Group. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 62% leaning bullish and 29% bearish. Among these notable options, 7 are puts, totaling $331,040, and 17 are calls, amounting to $992,307.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $510.0 to $610.0 for UnitedHealth Group during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for UnitedHealth Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across UnitedHealth Group's significant trades, within a strike price range of $510.0 to $610.0, over the past month.
<h3>UnitedHealth Group 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730223029_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$11.9</td>
<td>$11.3</td>
<td>$11.6</td>
<td>$610.00</td>
<td>$226.1K</td>
<td>926</td>
<td style="text-align: right;">210</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/08/24</td>
<td>$10.0</td>
<td>$9.3</td>
<td>$10.0</td>
<td>$570.00</td>
<td>$93.0K</td>
<td>76</td>
<td style="text-align: right;">105</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/08/24</td>
<td>$10.2</td>
<td>$9.3</td>
<td>$10.2</td>
<td>$570.00</td>
<td>$82.6K</td>
<td>76</td>
<td style="text-align: right;">186</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$7.95</td>
<td>$7.8</td>
<td>$7.95</td>
<td>$550.00</td>
<td>$79.5K</td>
<td>1.6K</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$18.9</td>
<td>$16.9</td>
<td>$18.58</td>
<td>$560.00</td>
<td>$74.2K</td>
<td>50</td>
<td style="text-align: right;">41</td>
</tr>
</tbody>
</table>

<h3>About UnitedHealth Group</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Having examined the options trading patterns of UnitedHealth Group, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is UnitedHealth Group Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,107,334, with UNH's price down by -0.44%, positioned at $562.78.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 73 days.</li>
</ul>
<h3>Professional Analyst Ratings for UnitedHealth Group</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $633.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald persists with their Overweight rating on UnitedHealth Group, maintaining a target price of $644. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $591. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on UnitedHealth Group, which currently sits at a price target of $650. 
&#x2A; An analyst from Keybanc downgraded its action to Overweight with a price target of $675. 
&#x2A; Consistent in their evaluation, an analyst from Stephens &amp; Co. keeps a Overweight rating on UnitedHealth Group with a target price of $605. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest UnitedHealth Group options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Smart Money Is Betting Big In UNH Options

"We continue to notify potentially impacted individuals as quickly as possible, on a rolling basis, given the volume and complexity of the data involved and the investigation is still in its final stages," the spokesperson said in an email.
&nbsp;
<a href="https://www.startribune.com/cyberattack-at-unitedhealth-subsidiary-change-healthcare-affected-100m-americans/601167324" title="https://www.startribune.com/cyberattack-at-unitedhealth-subsidiary-change-healthcare-affected-100m-americans/601167324">https://www.startribune.com/cyberattack-at-unitedhealth-subsidiary-change-healthcare-affected-100m-americans/601167324</a>

Reported Earlier, UnitedHealth Says Continues To Notify Individuals Potentially Impacted By Change Cyberattack As Quickly As Possible; Company Is In "Regular Communication" With The HHS, OCR And Other Regulators Regarding The Notification Process; Given The Volume And Complexity Of The Data Involved And The Investigation Is Still In Its Final Stages

In the latest quarter, 16 analysts provided ratings for UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">12</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $616.94, along with a high estimate of $675.00 and a low estimate of $591.00. A decline of 0.31% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1729620302_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive UnitedHealth Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$603.00</td>
<td>$604.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$609.00</td>
<td>$601.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$650.00</td>
<td>$680.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$605.00</td>
<td>$632.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$644.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$625.00</td>
<td>$640.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$595.00</td>
<td>$615.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$650.00</td>
<td>$675.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$610.00</td>
<td>$615.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$650.00</td>
<td>$675.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$675.00</td>
<td>-</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to UnitedHealth Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of UnitedHealth Group compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for UnitedHealth Group's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of UnitedHealth Group's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UNH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on UnitedHealth Group analyst ratings.</a>
<h2>All You Need to Know About UnitedHealth Group</h2>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
<h3>UnitedHealth Group: Financial Performance Dissected</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: UnitedHealth Group displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 6.61%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: UnitedHealth Group's net margin excels beyond industry benchmarks, reaching 4.31%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.79%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): UnitedHealth Group's ROA stands out, surpassing industry averages. With an impressive ROA of 1.48%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 0.84, UnitedHealth Group faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

16 Analysts Assess UnitedHealth Group: What You Need To Know

Barclays analyst Andrew Mok maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and lowers the price target from $604 to $603.

Price Target

Barclays Maintains Overweight on UnitedHealth Group, Lowers Price Target to $603

In a significant development in the health insurance industry, Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has reinitiated discussions to merge with Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), potentially creating a giant in the sector.
Talks, previously stalled over pricing disagreements, have resumed with a focus on a transformative consolidation that could reshape market dynamics.
According to a <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-10-18/cigna-resumes-merger-discussions-with-humana-after-talks-ended-last-year?sref=TBDibEcD" rel="noreferrer noopener">Bloomberg</a> report on Friday, the early talks about the merger would significantly expand Cigna&#8217;s footprint in Medicare Advantage alongside its commercial insurance prowess while leveraging Humana&#8217;s strong Medicare segment.
Also: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth&#8217;s Pharmacy Benefit Managers For Inflating Insulin Prices</a>
Last year, both <a target="_blank" href="https://www.benzinga.com/markets/equities/23/11/36007194/whats-going-on-with-healthcare-insurance-giant-cigna-stock-today" rel="noreferrer noopener">companies faced challenges</a> as they navigated federal pressures to reduce Medicare costs, severely impacting Humana&#8217;s market performance and valuation.
These resumed talks hint at a possible major realignment aiming to fortify their positions against competitors like UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) and&nbsp;CVS Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>).
The merger discussions are still in the nascent stages, with no decisions made. Both companies declined to comment on the ongoing negotiations.
A potential deal, estimated to be among the top five health insurance mergers, reflects a strategic shift in the industry focused on consolidation amid rising healthcare costs and stringent regulatory environments.
This deal could not only stabilize Humana&#8217;s declining Medicare enrollments but also enhance Cigna&#8217;s capabilities in managing more comprehensive healthcare plans.
Furthermore, a merger could ease the competitive pressure from the rapidly growing sectors of the industry, providing a robust challenge to established giants.
Humana&#8217;s stock value sharply declined due to lower-than-expected government reimbursements and increased demand for medical services. The merger is, therefore, potentially crucial for recovery and growth.
Price Action: CI stock is down 4.18% at $321.94, and HUM stock is up 0.88% at $269.50 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41409405/after-failed-confirmatory-trial-gilead-withdraws-us-accelerated-approval-of-trodelvy-as-bladder-c" target="_blank" rel="noreferrer noopener">After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer Treatment</a>.</li>
</ul>
Photo via Shutterstock

Rumors

Media

Cigna And Humana Revive Early Merger Talks After Year-Long Pause As Medicare Cost Pressure Looms

UnitedHealth Group&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unh#NYSE">UNH</a>) stock price pulled back following the Q3 earnings release in what can best be described as a temper tantrum. The results weren&#39;t bad, outpacing the consensus estimates and compounded by solid guidance, but the market wanted more, so it sold off.&nbsp;
The takeaway is that this healthy, dividend-paying growth machine is executing despite the headwinds and delivering value for investors; the post-release dip is a buying opportunity. Value building is expected to continue in Q4 and next year, suggesting new highs will be set soon - and a 100% increase is possible for long-term holders. Because the analysts are leading the market for this <a href="https://www.marketbeat.com/stocks/sectors/medical/">healthcare stock</a>, a new all-time high may be reached before the end of the year.&nbsp;
<h3>UnitedHealth Group Falls After Solid Report; The Rebound Has Already Started&nbsp;</h3>
UnitedHealth Group had<a href="https://www.marketbeat.com/stocks/NYSE/UNH/earnings/"> a solid quarter</a>, with revenue of $100.8 billion, rising more than 9% compared to the previous year. The revenue outpaced the consensus reported by MarketBeat.com by nearly 200 basis points on strength in both segments, which was driven by an increasing client base. The core UnitedHealth segment grew by 7.1%, led by a 12.7% increase at Optum. Strength in the UnitedHealth segment is due to an 8.8% increase in the number of people served; strength at Optum is due to an increased patient count in both sub-segments, compounded by deepening penetration.&nbsp;
The guidance news is mixed and central to the market&#39;s initial reaction. The company reported a higher-than-expected medical cost ratio of 85.2%, casting doubt on future profitability. However, operational quality offset the medical cost ratio increase, leaving the adjusted net margin flat compared to last year. The bottom line is that GAAP earnings are down due to one-offs, including the impact of the cyberattack in Q1. However, adjusted EPS grew by 9%, aligning with the top-line growth, sufficient to sustain the business health and capital return outlook.&nbsp;
Guidance is another sticky point for the market but ultimately favorable to the stock price. The company narrows its full-year EPS range by a nickel at the high end because of cyber attack costs and mitigation efforts. Still, the mid-point of guidance is above the consensus estimate, with top and bottom-line growth expected to persist through 2025.&nbsp;
<h3>The Analysts Lead UnitedHealth Group To New Highs</h3>
The <a href="https://www.marketbeat.com/stocks/NYSE/UNH/forecast/">analysts&#39; response</a> to UnitedHealth Group&#39;s Q3 results is mixed, with some lowering, some reaffirming, and some raising their price targets for the stock. The salient point is that the sentiment remains firm at Moderate Buy, and conviction is firming that new highs will soon be set.
The consensus price target implies a 7% upside from $570, sufficient to set a new high, and the revisions suggest a move into the high-end range is likely. The high-end range adds another 100 to 600 basis points to the 7% upside target.
Regarding capital return, the $8.40 annualized distribution yields a little over 1.0%, with shares near $570. The payout is a safe 30% of earnings in 2024, and the balance sheet is a fortress, so annual distribution increases should continue. The company is not a Dividend Aristocrat but is tracking in the right direction with 15 years of sustained increases to its credit. Investors with a 10-year or longer time horizon for holding UNH stock may see it included in the Dividend Aristocrat Index, another tailwind for price action. The distribution is compounded by repurchases, sufficient to offset share-based compensation and reduce the count incrementally in Q3.&nbsp;
<h2>The Technical Outlook: UNH Stock Confirms Its Uptrend</h2>
UNH stock&#39;s price plunge was not pretty, but it is still good news for investors. The plunge confirmed <a href="https://www.marketbeat.com/stock-ideas/undervalued-unitedhealth-group-wont-be-for-long/">support at a critical level</a>, making a sustained uptrend possible. The market for UNH broke out of a multi-year consolidation range over the summer. The post-earnings dip confirms support at the top of the range, indicating a continuation of the longer-term uptrend. In this scenario, the stock could rally higher for the next three years, gaining 50% to 100% in value at the peak.&nbsp;
<img alt="UnitedHealth Group UNH stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20241016130109_chart-unh-10162024.png" style="height:448px; width:624px" />
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/unitedhealth-group-pulls-back-into-a-healthy-buying-opportunity/">UnitedHealth Group Pulls Back Into a Healthy Buying Opportunity</a>&quot; first appeared on MarketBeat.

Technicals

UnitedHealth Group Pulls Back Into A Healthy Buying Opportunity

Several large insurers have reported higher-than-expected medical costs, particularly in their government-sponsored Medicaid plans, following the end of a pandemic-era policy that required insurers <a href="https://www.benzinga.com/news/earnings/24/10/41387258/3-medical-services-stocks-to-buy-to-navigate-industry-challenges">to keep members enrolled. </a>
The Details: The end of the COVID-19 public health emergency triggered significant changes to Medicaid coverage, including the end of the continuous enrollment provision, which prevented states from disenrolling members during the pandemic. Beginning on April 1, 2023, states began the process of redetermining eligibility for all Medicaid enrollees, which<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41388721/why-is-elevance-health-stock-trading-lower-on-thursday"> created a disparity</a> between payments from states and rising trends in medical expenses for insurers. 
Analysts at William Blair <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41388721/why-is-elevance-health-stock-trading-lower-on-thursday">recently noted</a> that large managed care organizations (MCOs) seem to be facing pressure regarding Medicaid utilization. At the same time, outdated data often determine the premiums they receive from states.
Read Next: <a href="https://www.benzinga.com/news/24/10/41385546/ftc-click-to-cancel-rule-makes-it-easy-to-end-subscriptions-what-it-means-for-netflix-planet-fitness">FTC &#8216;Click-To-Cancel&#8217; Rule Makes It Easy To End Subscriptions: What It Means For Netflix, Planet Fitness And More</a>
Effects on Insurers: Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) lowered its <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41388721/why-is-elevance-health-stock-trading-lower-on-thursday">annual profit forecast </a>Thursday due to persistently high medical costs tied to its Medicaid plans, which account for 20% of the company's total medical membership. 
&#8220;The issues impacting the Medicaid business are time-bound,&#8221; Elevance CEO Gail Boudreaux said on the company's earnings call.&nbsp;
CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) replaced its CEO on Friday and cut its <a href="https://www.benzinga.com/news/earnings/24/10/41399396/pharmacy-retailer-cvs-health-backs-away-from-annual-forecast-names-new-ceo">third-quarter outlook</a> to earnings of between $1.05 and $1.10, compared to the consensus estimate of $1.70. The company cited "elevated medical cost pressures in the Health Care Benefits segment" as a cause of the revision.&nbsp;&nbsp;
UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) reported its <a href="https://www.benzinga.com/news/earnings/24/10/41328272/unitedhealth-q3-earnings-revenue-and-eps-beat-revises-annual-profit-guidance-as-change-healthcare-c">third-quarter results </a>on Tuesday and also lowered its annual profit forecast as challenges across its government-supported health insurance businesses continue.&nbsp;
UnitedHealth's president and CFO John Rex pointed to "the continued timing mismatch between the current health status of Medicaid members and state rate updates" as an ongoing pressure point for the company.&nbsp;
"As a result of the lagging care activity data, as well as the annual rate cycle timing, updates remain well short of current care activity, a factor that for us was more pronounced through the period than anticipated," Rex said on the company's post-earnings conference call.&nbsp;
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41379867/european-central-bank-lowers-interest-rates-again-first-back-to-back-cuts-in-13-years">European Central Bank Lowers Interest Rates Again, First Back-To-Back Cuts In 13 Years</a></li>
</ul>
Image: Shutterstock&nbsp;

Earnings

Elevance, CVS, UnitedHealth Struggle With Rising Medical Costs After COVID-19 Medicaid Policy Ends

Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2024 Update

Scotiabank lowered the firm's price target on Myriad Genetics (MYGN) to $24 from $34 and keeps an Outperform rating on the shares. The firm lowered...

Myriad Genetics price target lowered to $24 from $34 at Scotiabank

Tracking Jeremy Grantham's GMO Capital Portfolio - Q3 2024 Update

Medicare to adjust disputed Star Rating measure: Bloomberg News

Medicare to adjust disputed Star Ratings measure: Bloomberg News

Chase Coleman's Tiger Global disclosed in an SEC filing its holdings as of September 30, 2024. Tiger's three new buys during the third quarter incl...

Tiger Global take new stake in Flutter, cuts stake in Uber

Tudor Investment adds Infinera, Trane, exits Disney, UnitedHealth, among top Q3 trades

Stephen Mandel's Lone Pine Capital disclosed in an SEC filing its holdings as of September 30, 2024. The fund's four new buys during the third quar...

Lone Pine buys UnitedHealth, exits Workday in Q3

Coatue Management top Q3 moves: cuts Nvidia, exits CRM & UNH, piles into Chinese stocks

Fidelity Magellan Fund Q3 2024 Review

AAPL

ADBE

ALAB

ARES

ASML

ASMLF

AVDX

BABA

CDNS

CPNG

CRWD

DASH

DELL

DXCM

EPAM

FLUT

FSLR

GOOG

GOOGL

INFN

ISRG

LRCX

MSFT

MYGN

NFLX

NONOF

ORCL

PYPL

QCOM

QLTY

SCHW

SHOP

SNPS

STNE

TEAM

TSLA

TSMWF

UBER

WDAY

WFCNP

Press Releases

UNITEDHEALTH GROUP INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of UnitedHealth Group Incorporated - UNH

UnitedHealth Group and Goodwill® Partner to Expand Career Pathways Training to Foster Healthier Communities

UNITEDHEALTH GROUP INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of UnitedHealth Group Incorporated - UNH

UnitedHealth Group Announces Earnings Release Date

UnitedHealthcare Community Plan of New Mexico invests $250,000 to provide integrated health care services to K-12 students

UNITEDHEALTH ALERT: Bragar Eagel & Squire, P.C. is Investigating UnitedHealth Group Incorporated on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

UnitedHealthcare Commits $335,000 to Idaho Organizations To Expand Health Care Workforce and Access To Care

Comments

UnitedHealth Group

Interés en corto

UnitedHealth Group (NYSE:UNH) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL